Loading...
Market
How many new competitors will emerge in Alzheimer's prevention for type 2 diabetes by end of 2025?
2
Resolution / Starting Odds
More than 3 competitors • 25%
2 to 3 competitors • 25%
1 competitor • 25%
No new competitors • 25%
Industry reports and announcements from pharmaceutical companies
Story
Ozempic Linked to 70% Lower Alzheimer's Risk in Type 2 Diabetes Patients
Oct 24, 2024, 12:14 PM
Novo Nordisk's diabetes drug Ozempic, which contains the active ingredient semaglutide, has been linked to a significantly reduced risk of being diagnosed with Alzheimer's disease among people with type 2 diabetes. The observational study found a 70% lower risk of Alzheimer's diagnosis compared to other diabetes medications, based on an analysis of medical records. This adds to the growing evidence of Ozempic's effects beyond type 2 diabetes and obesity, indicating potential benefits in neurodegenerative diseases. Wegovy, another drug containing semaglutide, may also reduce Alzheimer's risk.
View original story
Similar markets
None • 25%
1-2 companies • 25%
3-4 companies • 25%
More than 4 companies • 25%
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 5 new treatments • 25%
No new competitors • 25%
1-2 new competitors • 25%
3-4 new competitors • 25%
5+ new competitors • 25%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Adopted in US and EU • 25%
Adopted in US only • 25%
Adopted in EU only • 25%
Not adopted • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%